Age Related Macular Degeneration Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Age Related Macular Degeneration Pipeline Drugs Market Overview

Age related macular degeneration is the most common reason for vision loss in people aged above 50. It results in the depreciation of the macula which may lead to distorted or blurry central vision. The predisposing factors involved are age, smoking, sunlight, heredity, etc. Symptoms include the development of blind spots and hazy vision. The condition may be treated by photodynamic therapy, radiation therapy, and medication such as anti-angiogenic drugs.

The Age Related Macular Degeneration pipeline drugs market research report provides comprehensive information on the therapeutics under development for Age Related Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Age Related Macular Degeneration and features dormant and discontinued projects.

Key Targets Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor, Angiopoietin 2, Angiopoietin 1 Receptor, and Others
Key Mechanisms of Action Vascular Endothelial Growth Factor A Inhibitor, Vascular Endothelial Growth Factor Inhibitor, Angiopoietin 2 Inhibitor, Placenta Growth Factor Inhibitor, Angiopoietin 1 Receptor Agonist, and Others
Key Routes of Administration Intravitreal, Oral, Ophthalmic, Intraocular, and Others
Key Molecule Type Small Molecule, Monoclonal Antibody, Gene Therapy, Biologic, and Others
Leading Companies Nextgen Bioscience, Shanghai Novamab Biopharmaceuticals Co Ltd, YD Life Science Co, AmMax Bio Inc, and Others
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Age Related Macular Degeneration Pipeline Drugs Market Segmentation by Targets

The key targets in the Age Related Macular Degeneration pipeline drugs market are Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor, Angiopoietin 2, Angiopoietin 1 Receptor, and Others. Vascular Endothelial Growth Factor A had the highest number of products in development in the Age Related Macular Degeneration pipeline drugs market, in 2022.

Age Related Macular Degeneration Pipeline Drugs Market Analysis by Targets, 2022 (%)

Age Related Macular Degeneration Pipeline Drugs Market Analysis by TargetsFor more target insights into the Age Related Macular Degeneration pipeline drugs market, download a free report sample

Age Related Macular Degeneration Pipeline Drugs Market Segmentation by Mechanisms of Action

The key mechanisms of action in the Age Related Macular Degeneration pipeline drugs market are Vascular Endothelial Growth Factor A Inhibitor, Vascular Endothelial Growth Factor Inhibitor, Angiopoietin 2 Inhibitor, Placenta Growth Factor Inhibitor, Angiopoietin 1 Receptor Agonist, and Others. Vascular Endothelial Growth Factor A  Inhibitor led the Age Related Macular Degeneration pipeline drugs market in terms of MoA in 2022.

Age Related Macular Degeneration Pipeline Drugs Market Analysis by Mechanisms of Action, 2022 (%)

Age Related Macular Degeneration Pipeline Drugs Market Analysis by Mechanisms of ActionFor more MoA insights into the Age Related Macular Degeneration pipeline drugs market, download a free report sample

Age Related Macular Degeneration Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Age Related Macular Degeneration pipeline drugs market intravitreal, oral, ophthalmic, intraocular, and others. The intravitreal RoA had the highest number of Age Related Macular Degeneration drugs in development in 2022.

Age Related Macular Degeneration Pipeline Drugs Market Analysis by Routes of Administration, 2022 (%)

Age Related Macular Degeneration Pipeline Drugs Market Analysis by Routes of AdministrationFor more MoA insights into the Age Related Macular Degeneration pipeline drugs market, download a free report sample

Age Related Macular Degeneration Pipeline Drugs Market Segmentation by Molecule Types

The key molecule types in the Age Related Macular Degeneration pipeline drugs market are small molecule, monoclonal antibody, gene therapy, biologic, and others. Small molecule led the Age Related Macular Degeneration pipeline drugs market in terms of molecule type in 2022.

Age Related Macular Degeneration Pipeline Drugs Market Analysis by Molecule Types, 2022 (%)

Age Related Macular Degeneration Pipeline Drugs Market Analysis by Molecule TypesFor more molecule type insights into the Age Related Macular Degeneration drugs market, download a free report sample

Age Related Macular Degeneration Pipeline Drugs Market - Competitive Landscape

Some of the leading companies in the Age Related Macular Degeneration pipeline drugs market are Nextgen Bioscience, Shanghai Novamab Biopharmaceuticals Co Ltd, YD Life Science Co, AmMax Bio Inc, and others. Nextgen Bioscience is one of the companies with the highest number of Age Related Macular Degeneration drugs in development in 2022.

Age Related Macular Degeneration Pipeline Drugs Market Analysis by Companies, 2022 (%)

Age Related Macular Degeneration Pipeline Drugs Market Analysis by CompaniesTo know more about the leading Age Related Macular Degeneration pipeline drugs market players, download a free report sample

Key Segments Covered in this Report

Age Related Macular Degeneration Pipeline Drugs Target Outlook (No of Drugs, 2022)

  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factor
  • Angiopoietin 2
  • Angiopoietin 1 Receptor
  • Others

Age Related Macular Degeneration Pipeline Drugs MoA Outlook (No of Drugs, 2022)

  • Vascular Endothelial Growth Factor A Inhibitor
  • Vascular Endothelial Growth Factor Inhibitor
  • Angiopoietin 2 Inhibitor
  • Placenta Growth Factor Inhibitor
  • Angiopoietin 1 Receptor Agonist
  • Others

Age Related Macular Degeneration Pipeline Drugs RoA Outlook (No of Drugs, 2022)

  • Intravitreal
  • Oral
  • Ophthalmic
  • Intraocular
  • Others

Age Related Macular Degeneration Pipeline Drugs Molecule Type Outlook (No of Drugs, 2022)

  • Small Molecule
  • Monoclonal Antibody
  • Gene Therapy
  • Biologic
  • Others

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration.
  • The pipeline guide reviews pipeline therapeutics for Age Related Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Age Related Macular Degeneration therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Age Related Macular Degeneration therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Age Related Macular Degeneration

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Age Related Macular Degeneration.
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding the Age Related Macular Degeneration pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.

3SBio Inc
Abfero Pharmaceuticals Inc
Abzyme Therapeutics LLC
Acahealth Pharma and Biotech Co Ltd
Aerie Pharmaceuticals Inc
Alexion Pharmaceuticals Inc
Alkeus Pharmaceuticals Inc
Amarna Therapeutics BV
AMD Therapeutics LLC
AmMax Bio Inc
Amyndas Pharmaceuticals LLC
Amytrx Therapeutics Inc
AngioGenex Inc
Anida Pharma Inc
Applied Genetic Technologies Corp
Aptamer Sciences Inc
Ascentage Pharma Group International
Autophagy Science Co Ltd
Avirmax Inc
Baltymas UAB
Beijing StarMab BioMed Technology Ltd
BellBrook Labs LLC
BenoBio Co Ltd
Biokine Therapeutics Ltd
Biomics Biotechnologies Co Ltd
BioXpress Therapeutics SA
Bonac Corp
BrainEver SAS
Breye Therapeutics ApS
Bridge Biotherapeutics Inc
Broadwing Bio
Carmine Therapeutics Inc
CDR-Life Inc
Celon Pharma SA
Celros Biotech Co Ltd
Character Biosciences Co
Charlesson LLC
Chong Kun Dang Pharmaceutical Corporation
Clayton Biotechnologies Inc
Complement Therapeutics Ltd
ConeSight Therapeutics
Curative Biotechnology Inc
CureLab Oncology Inc
Daiichi Sankyo Co Ltd
EirGenix Inc
Epygen Biotech Pvt Ltd
Excitant Therapeutics LLC
Exegenesis Bio Inc
Eye Bio Korea Co Ltd
F. Hoffmann-La Roche Ltd
Feramda Ltd
Galimedix Therapeutics Ltd
Generoath Co Ltd
Glaceum Inc
Great Bay Bio Holdings Ltd
Hanlim Pharm Co Ltd
ICM Co Ltd
Iconic Therapeutics Inc
Immupharma Plc
Inflammasome Therapeutics Inc
Inflammx Therapeutics Inc
Jecho Biopharmaceuticals Co Ltd
Jenivision Inc
JW Pharmaceutical Corp
Kala Pharmaceuticals Inc
Kiora Pharmaceuticals Inc
Lead Discovery Center GmbH
Lineage Cell Therapeutics Inc
Lysoclear Inc
Mabion SA
maintect GmbH
MD Healthcare Inc
MDimune Inc
Mediolanum farmaceutici SpA
MetiMedi Pharmaceuticals Co Ltd
MitoImmune Therapeutics Inc
Mitsubishi Tanabe Pharma Corp
Mor Research Applications Ltd
Nextgen Bioscience
NGM Biopharmaceuticals Inc
Novartis AG
Noveome Biotherapeutics Inc
OliPass Corporation
Omeros Corp
Oncosimis Biotech Pvt Ltd
Opsis Therapeutics LLC
Paras Biopharmaceuticals Finland Oy
Perceive Biotherapeutics Inc
Phanes Therapeutics Inc
PharmAbcine Inc
Phio Pharmaceuticals Corp
Phision Therapeutics
PlantForm Corp
Pleryon Therapeutics Ltd
Regeneron Pharmaceuticals Inc
Retrotope Inc
RheinCell Therapeutics GmbH
Rophibio Inc
Rudacure Co Ltd
SeaBeLife Spas
Semathera Inc
Shanghai Novamab Biopharmaceuticals Co Ltd
SIFI SpA
SmartinBio
Splash Pharmaceuticals Inc
Sustained Nano Systems LLC
Suzhou Ribo Life Sciences Co Ltd
Suzhou Stainwei Biotech Inc
Sylentis SAU
TALLC Inc
TechnoPhage SA
Tianchen Biopharmaceutical (Suzhou) Co Ltd
TreeFrog Therapeutics SAS
Trican Biotechnology Co Ltd
Uni-Bio Science Group Ltd
Unity Biotechnology Inc
Valitor Inc
ViGeneron GmbH
Visgenx Inc
Wellstat Ophthalmics Corp
YD Life Science Co
Zhejiang Doer Biologics Corp
Zhuhai Qiwei Biotechnology Co Ltd
Zydus Lifesciences Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Age Related Macular Degeneration – Overview

Age Related Macular Degeneration – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Age Related Macular Degeneration – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Age Related Macular Degeneration – Companies Involved in Therapeutics Development

Age Related Macular Degeneration – Drug Profiles

Age Related Macular Degeneration – Dormant Projects

Age Related Macular Degeneration – Discontinued Products

Age Related Macular Degeneration – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Age Related Macular Degeneration, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Target, 2022 (Contd..2)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Age Related Macular Degeneration – Dormant Projects, 2022

Age Related Macular Degeneration – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Age Related Macular Degeneration, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Age Related Macular Degeneration Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Age Related Macular Degeneration Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Age Related Macular Degeneration Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Age Related Macular Degeneration Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.